RT-QuIC Assay Differentiating Synucleinopathies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for differentiating Parkinson's Disease (PD) and Dementia with Lewy bodies (DLB) are inadequate, relying on physical characteristics rather than molecular evidence, and there is a need for improved methods to diagnose and treat synucleinopathies effectively.
Innovation Solution
The use of C-terminal truncations of monomeric αSyn species in the real-time quaking-induced conversion (RT-QuIC) assay to differentiate PD from DLB by analyzing the seeding activity of aqueous-soluble and detergent-soluble fractions from brain tissue samples, employing recombinant αSyn forms such as αSyn 1-130 and αSyn 1-115, and characterizing the aggregation products through proteinase K digestion and electron microscopy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If physical characteristics are used for diagnosis, then the diagnostic method is simple, but the differentiation accuracy between PD and DLB is insufficient
Solution Approach 1:
The patent replaces physical/clinical characteristic assessment with a molecular biology-based diagnostic system. It uses RT-QuIC assay to detect and characterize α-synuclein aggregate seeds from brain tissue, providing molecular evidence for differentiation between PD and DLB. This substitution of diagnostic approach increases measurement precision while managing complexity through standardized laboratory procedures.
Solution Approach 2:
The patent changes the diagnostic parameters from physical characteristics to molecular parameters. Specifically, it measures α-synuclein aggregate properties including seeding activity, aggregation kinetics, and proteinase K resistance as diagnostic parameters. These molecular parameters provide more precise differentiation capability compared to physical characteristics.
2Measurement precision
If molecular evidence methods are used, then the diagnosis precision is improved, but the complexity of the diagnostic system increases
Solution Approach 1:
The patent segments the diagnostic process into distinct functional steps: tissue sample preparation, fractionation (aqueous-soluble and detergent-soluble), RT-QuIC assay, and characterization. This segmentation allows each step to be optimized independently and facilitates standardization, managing system complexity while maintaining high precision.
Solution Approach 2:
The patent uses recombinant α-synuclein forms (such as αSyn 1-130 and αSyn 1-115) as intermediaries in the RT-QuIC assay. These recombinant proteins serve as substrates that convert into aggregates seeded by patient samples, enabling detection and characterization of pathogenic α-synuclein species without directly analyzing the complex disease state.
3Measurement precision
If C-terminal truncations of αSyn are used in RT-QuIC assay, then the differentiation between PD and DLB is enhanced, but the assay complexity increases
Solution Approach 1:
The patent applies local quality by using specific C-terminal truncated forms of α-synuclein (αSyn 1-130 and αSyn 1-115) as substrates in the RT-QuIC assay. These truncated variants have different aggregation properties and strand configurations that are selectively enhanced in certain synucleinopathies, providing localized diagnostic specificity for differentiating PD from DLB.
Solution Approach 2:
The patent changes the substrate parameter in the RT-QuIC assay from full-length α-synuclein to C-terminal truncated forms. This parameter change modifies the aggregation kinetics and final aggregate structure, enabling enhanced differentiation capability. The truncated forms provide distinct aggregation patterns that facilitate more precise diagnosis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the differentiation of PD and DLB based on the seeding activity and aggregation properties of αSyn species, providing a molecular basis for diagnosis and potentially informing treatment strategies, with the RT-QuIC assay demonstrating higher sensitivity and specificity when using detergent-soluble fractions from the frontal cortex.
Implementation Method 1
real-time quaking-induced conversion (RT-QuIC) assay
Implementation Method 2
characterizing the aggregation products through proteinase K digestion
Implementation Method 3
characterizing the aggregation products through proteinase K digestion and electron microscopy
Implementation Method 4
analyzing the seeding activity of aqueous-soluble and detergent-soluble fractions
Data Source
AI summary
Provided are methods of diagnosis and differentiation of and between PD and DLB tissue samples.